RAPT Therapeutics (NASDAQ:RAPT) Receives “Neutral” Rating from HC Wainwright

RAPT Therapeutics (NASDAQ:RAPT)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a research note issued on Tuesday,Benzinga reports.

A number of other equities analysts have also commented on the company. UBS Group lowered their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $8.00 to $2.00 in a research note on Monday. Finally, JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.86.

RAPT Therapeutics Trading Down 39.4 %

Shares of NASDAQ RAPT opened at $1.75 on Tuesday. The firm has a market cap of $61.08 million, a P/E ratio of -0.56 and a beta of 0.33. RAPT Therapeutics has a 1-year low of $1.30 and a 1-year high of $27.35. The business’s 50 day moving average is $1.97 and its 200-day moving average is $3.10.

Institutional Investors Weigh In On RAPT Therapeutics

A number of large investors have recently modified their holdings of the business. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after purchasing an additional 3,824 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of RAPT Therapeutics during the first quarter valued at $97,000. EntryPoint Capital LLC acquired a new position in shares of RAPT Therapeutics during the first quarter worth $161,000. Bank of New York Mellon Corp grew its stake in shares of RAPT Therapeutics by 24.0% in the second quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock worth $349,000 after purchasing an additional 22,175 shares during the last quarter. Finally, Los Angeles Capital Management LLC increased its holdings in RAPT Therapeutics by 66.2% in the second quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock valued at $258,000 after purchasing an additional 33,692 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.